UI Hospitals and Clinics
Participants in this study have been diagnosed with cancer and have advanced nonfunctional neuroendocrine tumors. This is a voluntary study to find out if the drug everolimus (Afinitor®) is sage and has beneficial effects in people who have this disease. About 279 patients will join in this study at around 120 research clinics in several countries around the world.
Pam Zehr, 319-353-8914
We welcome your feedback! Please help us improve your experience on our website by completing a brief survey.